Tamoxifen and the Risk of Parkinson's Disease in Female Patients with Breast Cancer in Asian People: A Nationwide Population-Based Study.
10.4048/jbc.2017.20.4.356
- Author:
Chien Tai HONG
1
;
Lung CHAN
;
Chaur Jong HU
;
Chien Min LIN
;
Chien Yeh HSU
;
Ming Chin LIN
Author Information
1. Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
Parkinson disease;
Tamoxifen
- MeSH:
Asian Continental Ancestry Group*;
Breast Neoplasms*;
Breast*;
Female*;
Humans;
National Health Programs;
Neurodegenerative Diseases;
Parkinson Disease*;
Proportional Hazards Models;
Tamoxifen*
- From:Journal of Breast Cancer
2017;20(4):356-360
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson's disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan's National Health Insurance Research Database. METHODS: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. RESULTS: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p=0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). CONCLUSION: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.
